TMPRSS2 and prostate cancer: Tumor SC_9009 expressed a fusion transcript involving the 5′ exons of TMPRSS2 and 3′ exons of ERG, consistent with the commonly observed TMPRSS2-ETS family rearrangements that occur in 40– 60% of prostate cancers [26].